(Natural News) Astonishingly, it is rapidly becoming apparent in the aftermath of the Dr. Bryan Ardis revelations about snake venom origins for covid-19 that many people — even some in alt media — are completely unaware that snake venom is commonly used as the starting point for pharmaceutical research.
Earlier today, a UK company literally named “Venomtech” announced a massive venom peptide and venom fragment library to be used for drug discovery by pharmaceutical companies (as well as pesticide used for agricultural companies).
The news was widely covered in the biotech media, including at News-Medical.net, which published the announcement, “Venomtech announces new drug development collaboration with Charles River
From that announcement:
Venomtech is collaborating with Charles River Laboratories, International Inc. to help drug developers explore venom-derived compounds for a wide range of therapeutic targets. This newly formed collaboration will bring together Venomtech’s biology expertise and vast venom-derived peptide library, with Charles River’s drug development and screening knowhow, providing pharmaceutical manufacturers with a one-stop service to explore this unique natural resource.
Venomtech’s Targeted-Venom Discovery Array™ (T-VDA™) libraries provide researchers with a straightforward solution to rapidly screen thousands of individual venom fragments, with each array specifically designed to maximise hits for a specific target.
The announcement carries this statement from Venomtech CEO Paul Grant:
Venomtech has been at the forefront of venom research for drug discovery for more than a decade… we can now showcase our innovative technology, introducing the wider industry to the potential of venoms for the successful delivery of more leads, more quickly, for a broad range of [cellular] targets.
…we can now offer our clients access to bespoke venom libraries, potentially accelerating their [drug] discovery pipelines using this powerful natural resource.
The Venomtech company is described as follows:
Venomtech is a global leader for venom research enterprises, based out of world-class laboratories at Discovery Park in Kent, UK.
…[we are] helping our customers worldwide make pioneering advances in drug discovery, crop protection, and cosmetics. We have the largest library of naturally sourced venom-derived compounds in the UK, from a growing collection of vertebrate and invertebrate species
Note that Venomtech’s clients include pharmaceutical companies, pesticides companies and cosmetic product manufacturers. Venom-based molecules are widely used in drug research and other areas of biotech.
So to those in the corporate media — and even in alt media — who are expressing shock and dismay at Dr. Ardis claiming that snake venom is the most likely origin for research into SARS-CoV-2 gain-of-function enhancement or even covid vaccines, you are ignorant of the state of the art in biosciences.
The use of snake venom in pharmaceuticals isn’t a “conspiracy theory.” It’s a common practice, representing what most bioscience experts would describe as the cutting edge of drug discovery.
For the record, by the way, we are not ascribing any nefarious accusations to the Venomtech company here. We mention them solely to prove to any skeptics that snake venom is, in fact, widely used as a resource for pharmaceutical development (and it has been for decades).
What Dr. Ardis has claimed is not science fiction. It is the state of bioscience in 2022.
Anyone dismissing the “snake venom” theory in relation to covid treatments or vaccines is flatly ignorant of the resources used in today’s drug discovery pipelines.
20,000 varieties of venom peptides…
Read full story here: Source: VenomTech company announces massive library of SNAKE VENOM peptides for pharmaceutical development; “nanocarriers” stabilize snake venom in WATER (PubMed) – NaturalNews.com